|Assessment Status||Rapid Review complete|
|Indication||Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. For patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.|
|Rapid review commissioned||10/07/2014|
|Rapid review completed||12/08/2014|
|Rapid review outcome||Full pharmacoeconomic evaluation recommended at the submitted price.|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.